FLORENCE, Italy, May 22, 2016 /PRNewswire/– ResMed (NYSE: RMD) today announced primary results from  a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology’s 2016 Annual Heart Failure Congress. CAT-HF assessed whether the…

Source: http://www.prnewswire.com/news-releases/adaptive-servo-ventilation-asv-therapy-suggests-positive-cardiovascular-outcomes-for-people-with-sleep-disordered-breathing-and-heart-failure-with-preserved-ejection-fraction-in-phase-ii-study-300272791.html

This entry was posted on Sunday, May 22nd, 2016 at 1:40 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.